

**Question for written answer E-003257/2022
to the Commission**

Rule 138

Cristina Maestre Martín De Almagro (S&D)

Subject: Funding of research into myalgic encephalomyelitis and multiple chemical sensitivity

In Europe, more than two million people suffer from myalgic encephalomyelitis. In addition to this, they suffer from a problem that aggravates their illness, namely the lack of expertise among health professionals themselves. There is also a lack of diagnostic tests, as none have yet been approved by the European Medicines Agency, making it impossible to access appropriate treatment.

The problem is even more serious for those with multiple chemical sensitivity, since – unlike Spain, Germany and Denmark – not all EU Member States recognise this condition as a disease. This makes them invisible to their health systems.

In both cases, patients face not only the disease, but also social stigma. The lack of information and awareness of both diseases means that those suffering from them are not only rendered invisible but also discriminated against owing to the lack of awareness of both diseases.

Given the precarious situation of these patients and their families,

will the Commission approve specific funding from the European budget for research, training for professionals, diagnostic tests and awareness-raising campaigns for these two diseases?